6.2 Exclusion Criteria 
6.2.1 Patients receiving autologous BMT with marrow purging on the 
PAMMYLA or BANG protocols 
6.2.2 Patients on whom the harvest yield < 3 x 10* cells/kg. 
7.0 TREATMENT PLAN 
The treatment plan and supportive care is described in the primary autograft protocol 
specific for the patient’s malignancy. 
8.0 PATIENT EVALUATION 
8.1 Regeneration of Cryopreserved Autologous Marrow 
In the absence of engraftment at 30 days (Neutrophils < 100/mm^) patients will 
receive a 10 course of G-CSF. If ANC remains < 100/mm*, the reserve, 
un manipulated marrow aliquot will be returned. The reserve marrow may be 
returned earlier in the presence of significant infectious complications after 
discussion with the P.I. of the protocol. 
When marrow is obtained to assess engraftment and disease progression, 
additional cultures will analyze which marker genes are present in progenitor cells 
and in what lineages. We will note time to engraftment of 100 neutrophils and 
500 neutrophils and the contribution of each aliquot of marrow at these times, 
using semiquantitative PCR. Patients will also be monitored at weekly intervals 
for 12 weeks, monthly intervals for 6 months and annually thereafter for 5 years 
for the long-term persistence of cells containing the marker genes in the 
peripheral blood (PB) using FACS sorted populations. PB will be separated into 
T cells, B cells, monocytes and granulocytes using appropriate monoclonal 
antibodies (MAb), and each lineage examined for the proviruses. Again, 
clonogenic analyses of progenitor cells grown in methylcellulose will be used to 
compare the contribution of each marrow aliquot to reconstitution. 
8.2 Other Studies. 
8.2.1 The following investigations will be obtained pre infusion, then 3 x 
weekly for 6 weeks, then weekly for 6 weeks then monthly for 1 year. 
CBC and diff 
Recombinant DNA Research, Volume 19 
[495] 
